Can Moderna Achieve Its Most Ambitious Goal Yet?
(NASDAQ: MRNA) and ambition seem to go hand and hand. The company doesn't fear taking on challenges, as it demonstrated during the earliest days of the pandemic when it brought its coronavirus vaccine from the drawing board to market in less than a year. Investors rewarded the biotech company for its audacity and scientific strengths, driving up the share price by 1,700% in just 1 1/2 years..
Recent times have been more difficult for Moderna shares, though. As we head toward a post-pandemic world and demand for coronavirus vaccines declines, investors have worried about Moderna's dependence on its one and only product. As a result, the stock has retreated, slipping about 40% this year.
But Moderna's most exciting days actually may be ahead rather than in the past -- at least, if the company reaches its most ambitious goal yet. Can it happen?
Source Fool.com
Moderna Inc. Aktie
Starkes Buy-Sentiment bei Moderna Inc. mit 21 Buy- gegenüber 2 Sell-Einschätzungen.
Das Kursziel von 129 € für Moderna Inc. weist auf eine Steigerung von über 50% gegenüber dem aktuellen Kurs von 81.2 € hin.
